394 related articles for article (PubMed ID: 11929809)
21. Von Hippel-Lindau syndrome. A pleomorphic condition.
Friedrich CA
Cancer; 1999 Dec; 86(11 Suppl):2478-82. PubMed ID: 10630173
[TBL] [Abstract][Full Text] [Related]
22. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma.
Foster K; Prowse A; van den Berg A; Fleming S; Hulsbeek MM; Crossey PA; Richards FM; Cairns P; Affara NA; Ferguson-Smith MA
Hum Mol Genet; 1994 Dec; 3(12):2169-73. PubMed ID: 7881415
[TBL] [Abstract][Full Text] [Related]
23. Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas.
Vortmeyer AO; Lubensky IA; Fogt F; Linehan WM; Khettry U; Zhuang Z
Am J Pathol; 1997 Oct; 151(4):951-6. PubMed ID: 9327728
[TBL] [Abstract][Full Text] [Related]
24. Mutational analysis of the von hippel lindau gene in clear cell renal carcinomas from tuberous sclerosis complex patients.
Duffy K; Al-Saleem T; Karbowniczek M; Ewalt D; Prowse AH; Henske EP
Mod Pathol; 2002 Mar; 15(3):205-10. PubMed ID: 11904337
[TBL] [Abstract][Full Text] [Related]
25. The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis.
Decker HJ; Weidt EJ; Brieger J
Cancer Genet Cytogenet; 1997 Jan; 93(1):74-83. PubMed ID: 9062583
[TBL] [Abstract][Full Text] [Related]
26. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.
Igarashi H; Esumi M; Ishida H; Okada K
Cancer; 2002 Jul; 95(1):47-53. PubMed ID: 12115316
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of biallelic inactivation of the von Hippel-Lindau tumor suppressor gene VHL in patients of renal cell carcinoma patient].
Liu N; Gong K; Zhang N; Guo HF; Na X; Wu G; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Jan; 43(2):115-7. PubMed ID: 15771820
[TBL] [Abstract][Full Text] [Related]
28. Meningioma showing VHL gene inactivation in a patient with von Hippel-Lindau disease.
Kanno H; Yamamoto I; Yoshida M; Kitamura H
Neurology; 2003 Apr; 60(7):1197-9. PubMed ID: 12682336
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
30. Somatic mutations of the von Hippel-Lindau tumor suppressor gene and loss of heterozygosity on chromosome 3p in human glial tumors.
Kanno H; Shuin T; Kondo K; Yamamoto I; Ito S; Shinonaga M; Yoshida M; Yao M
Cancer Res; 1997 Mar; 57(6):1035-8. PubMed ID: 9067265
[TBL] [Abstract][Full Text] [Related]
31. Von Hippel-Lindau disease and sporadic renal cell carcinoma.
Zbar B
Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521
[TBL] [Abstract][Full Text] [Related]
32. Deletion of chromosome 3p14.2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma.
Sükösd F; Kuroda N; Beothe T; Kaur AP; Kovacs G
Cancer Res; 2003 Jan; 63(2):455-7. PubMed ID: 12543802
[TBL] [Abstract][Full Text] [Related]
33. VHL and FHIT locus loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significance.
Velickovic M; Delahunt B; Störkel S; Grebem SK
Cancer Res; 2001 Jun; 61(12):4815-9. PubMed ID: 11406557
[TBL] [Abstract][Full Text] [Related]
34. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
35. Von Hippel-Lindau disease.
Sano T; Horiguchi H
Microsc Res Tech; 2003 Feb; 60(2):159-64. PubMed ID: 12539169
[TBL] [Abstract][Full Text] [Related]
36. Tongue cancer patients have a high frequency of allelic loss at the von Hippel-Lindau gene and other loci on 3p.
Asakawa T; Esumi M; Endo S; Kida A; Ikeda M
Cancer; 2008 Feb; 112(3):527-34. PubMed ID: 18072267
[TBL] [Abstract][Full Text] [Related]
37. Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney.
Yoshida M; Yao M; Ishikawa I; Kishida T; Nagashima Y; Kondo K; Nakaigawa N; Hosaka M
Genes Chromosomes Cancer; 2002 Dec; 35(4):359-64. PubMed ID: 12378530
[TBL] [Abstract][Full Text] [Related]
38. Biallelic inactivation of the von Hippel-Lindau tumor suppressor gene in sporadic renal cell carcinoma.
Hamano K; Esumi M; Igarashi H; Chino K; Mochida J; ISHIDA And H; Okada K
J Urol; 2002 Feb; 167(2 Pt 1):713-7. PubMed ID: 11792959
[TBL] [Abstract][Full Text] [Related]
39. Molecular analysis as a tool in the differential diagnosis of VHL disease-related tumors.
Gijtenbeek J; Jacobs B; Boots-Sprenger S; Bonne A; Lenders J; Küsters B; Wesseling P; Jeuken J
Diagn Mol Pathol; 2005 Jun; 14(2):115-20. PubMed ID: 15905696
[TBL] [Abstract][Full Text] [Related]
40. Somatic mosaicism in von Hippel-Lindau Disease.
Murgia A; Martella M; Vinanzi C; Polli R; Perilongo G; Opocher G
Hum Mutat; 2000 Jan; 15(1):114. PubMed ID: 10612832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
